Acalabrutinib Plus BR Leads to High CR Rates in Treatment-Naive, Relapsed/Refractory MCL
The addition of acalabrutinib to bendamustine and rituximab demonstrated potent and durable responses despite a high incidence of grade 3/4 adverse effects in patients with previously untreated and relapsed/refractory mantle cell lymphoma.
Datopotamab Deruxtecan Plus Pembrolizumab With or Without Chemo Produces Responses in Advanced NSCLC
Combination treatment consisting of datopotamab deruxtecan and pembrolizumab with or without platinum-based chemotherapy generated responses as first- or second-line treatment for patients with advanced or metastatic non–small cell lung cancer.
Talazoparib/Enzalutamide Combo Significantly Improves rPFS in HRR Gene–Altered mCRPC
The combination of talazoparib and enzalutamide resulted in a statistically significant and clinically meaningful improvement in radiographic progression-free survival when used as a first-line therapy for patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.
IBI351 Demonstrates Early Antitumor Activity and Tolerability in KRAS G12C+ Advanced NSCLC
The recommended phase 2 dose of IBI351 monotherapy had favorable safety and encouraging efficacy signals when administered to patients with advanced KRAS G12C–mutated non–small cell lung cancer, according to updated data from a phase 1 dose-escalation study.
Cemiplimab With or Without Chemotherapy Provides Long-Term Clinical Benefit in Locally Advanced NSCLC
First-line cemiplimab monotherapy or in combination with platinum-based chemotherapy conferred long-term clinical benefit to patients with unresectable, locally advanced non–small cell lung cancer who were ineligible for concurrent chemoradiation.
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer
Dostarlimab plus standard-of-care chemotherapy generated a significant improvement in progression-free survival vs chemotherapy alone for patients with recurrent endometrial cancer, including those with mismatch repair–deficient, microsatellite instability–high tumors.
Niraparib Maintenance Does Not Produce Long-term OS Benefit in Recurrent Ovarian Cancer
Maintenance niraparib did not produce a statistically significant overall survival benefit compared with placebo in patients with recurrent ovarian cancer, according to data from an updated exploratory OS analysis of the phase 3 ENGOT-OV16/NOVA study.
Iomab-B Prior to Allogeneic HCT Improves Durable Complete Remission Rate in Older Patients With R/R AML
High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.
Orca-T Leads to High RFS Rates in Acute Leukemias and MDS
Treatment with the cellular therapy Orca-T produced an improved graft-vs-host-disease and relapse-free survival rate in patients with high-risk myelodysplastic syndrome or acute leukemias.
Real-world OS Rates in aGVHD Increase in Ruxolitinib Treatment Era
Ruxolitinib induced clinically meaningful overall survival improvements by decreasing non-relapse mortality rates in patients with acute graft-vs-host-disease.
bTACE Plus Lenvatinib and MWA Produces Responses, Tolerability in HCC
Blank-microsphere transarterial chemoembolization plus low-dose lenvatinib and sequential microwave ablation elicited responses and a tolerable safety profile in patients with large hepatocellular carcinoma.
Leading The Field of Rare Ovarian Cancers to New Heights
During his career, David M. Gershenson, MD, has helped turn ovarian cancer
treatment into an evidence-based field and built better therapies through an
improved biological understanding of the disease.
Amid Withdrawal News, Final DREAMM-2 Analysis Confirms Durability of Belantamab Mafotodin Monotherapy in Relapsed/Refractory Multiple Myeloma
Single-agent belantamab mafodotin continued to produce rapid, deep, and durable responses in patients with relapsed/refractory multiple myeloma.
Addition of Neoadjuvant Pembrolizumab Improves EFS in Resectable Melanoma
Compared with adjuvant pembrolizumab alone, the addition of neoadjuvant pembrolizumab significantly improved event-free survival outcomes for patients with stage III-IV melanoma with a hazard ratio of 0.58.
Frontline Tislelizumab Demonstrates Noninferior OS Vs Sorafenib in Unresectable HCC
Tislelizumab monotherapy provided a clinically meaningful overall survival benefit that was noninferior to sorafenib and showcased a favorable toxicity profile when used as a frontline treatment for patients with unresectable hepatocellular carcinoma.
Isatuximab Plus Pomalidomide/Dexamethasone Maintains OS Benefit in R/R Myeloma
The addition of isatuximab to pomalidomide and low-dose dexamethasone continued to demonstrate improved overall survival in patients with relapsed/refractory multiple myeloma.
Isatuximab Under Evaluation in Real-World Study in Relapsed/Refractory Multiple Myeloma
Treatment with standard-of-care isatuximab in patients with relapsed/refractory multiple myeloma is being evaluated in a real-world trial,
Durvalumab/Tremelimumab Combo Provides OS Benefit in First-Line Metastatic NSCLC
The combination use of first-line durvalumab plus tremelimumab for the treatment of patients with metastatic non–small cell lung cancer improved overall survival compared with standard-of-care chemotherapy.
Lenvatinib Plus Pembrolizumab Produces Consistent Efficacy in East Asian Subset With Advanced RCC
The combination of lenvatinib and pembrolizumab produced similar efficacy and safety profiles in an East Asian subgroup of patients with advanced renal cell carcinoma.
Cilta-Cel Demonstrates Durable Responses at 2 Years Across Multiple Subgroups in R/R Myeloma
Data from a longer follow-up analysis of the phase 1/2 CARTITUDE-1 trial demonstrated that all evaluated subgroups of patients with relapsed/refractory multiple myeloma maintained durable responses with ciltacabtagene autoleucel.
Additional Research Efforts Required to Establish New Therapeutic Options for Low-Risk MDS
Because standardized treatment approaches have not been established for patients with low-risk myelodysplastic syndromes and limited options are available to those with erythropoietin failure, the need for varied clinical trials is underscored.
Real-World Data Highlight Utility of Axi-Cel/Tisa-Cel in DLBCL
In the first few years of their availability in the United States, axicabtagene ciloleucel and tisagenlecleucel have been used to mostly treat patients with diffuse large b-cell lymphoma in the outpatient setting who are receiving the CAR T-cell therapies prior to failure on 2 prior lines of therapy.
Regorafenib/Pembrolizumab Combination Yields Encouraging Results in Advanced HCC
The combination of regorafenib plus pembrolizumab in the first-line setting for patients with advanced hepatocellular carcinoma showed encouraging anti-tumor activity with a disease control rate of 91%, and did not display any new safety signals.
Tucatinib Concentrations in CSF Demonstrated in HER2+ Metastatic Breast Cancer
Evidence of tucatinib and its predominant metabolite, ONT-993, were detectable in the cerebrospinal fluid of patients with leptomeningeal metastasis HER2+ positive breast cancer marking a first for tucatinib distribution into the CSF seen in this patient population.
Ruxolitinib Delivered at Maximum Dose Peri-Transplant Proves Safe in Myelofibrosis
February 10, 2021 - The JAK 1/2 inhibitor ruxolitinib, when given at a maximum dose of 10 mg peri-transplant, has been shown to be safe and feasible in patients with myelofibrosis.
GI AEs Associated With Oral Paclitaxel Plus Encequidar Subside with Antiemetics, Loperamide in Metastatic Breast Cancer
December 11, 2020 - Gastrointestinal adverse events that occurred in patients with metastatic breast cancer who were treated with oral paclitaxel and encequidar can be managed by the use of 5- HT3 inhibitors and early intervention with loperamide.
Regardless of Timing, Smoking Cessation Before Lung Cancer Diagnosis Shows Survival Benefit
People who quit smoking at any time, even up to 2 years before a lung cancer diagnosis, have increased chances of survival after their diagnosis, according to data during a 2020 ASCO Virtual Scientific Program press briefing.
Lung Responses to Atezolizumab/Bevacizumab Linked With OS in HCC and Pulmonary Metastasis
Second-Line Regorafenib Demonstrates Safety in Advanced HCC, Irrespective of Prior Treatment
First-line Toripalimab Plus Sorafenib Elicits Responses in Unresectable Hepatocellular Carcinoma
Data for Luspatercept Highlight Evolving Treatment Landscape in Lower-Risk MDS
2 Clarke Drive Cranbury, NJ 08512